
# Changes in creatine kinase values in the serum of mothers of Duchenne muscular dystrophy patients

## Mohammad Obai'd Al-Muhammady , Saa'd Merza Al-Aaraji Ahlam K. Abood. College of Medicine. University of Babylon.



#### **Abstract**

Duchenne Muscular Dystrophy(DMD) is a sever x-chromosome linked degenerative disease of muscles affect boys due to mutations at a specific locus on the short arm of the X-chromosome. In the early stages of disease the affected young boys show loss of strength in their proximal muscles leading to waddling gait, to difficulty in standing up and eventually to very sever weakness.

Serum creatine kinase (CK) levels were measured in nineteen women who are mothers of DMD patients and compared with another serum CK of nineteen women with negative history of DMD(control group). The results indicate that serum CK levels of patient 's mothers are significantly higher than serum CK values of control group, and the serum CK values have markedly increased in52.1% of the patient's mothers, this lead to conclusion that 52.1% of these patient's mothers are carriers for disease and 47.9% are due to new mutations which may caused by the environmental factors.

#### الخلاصة

مرض الاعتلال العضلي هو واحد من الامراض الخطيرة المرتبطة وراثيا بكروموسوم- أكس والذي يؤثر على الذكور خاصة بسبب طفرة بموقع خاص بالذراع القصير لكروموسوم -أكس .هذا المرض يظهر بوقت مبكر من العمر وعادة يكون بفقدان القوة بعضلات الاطراف ممايؤدي الى خلل في المشي وصعوبة في الوقوف واحيانا "الى درجة عالية من من الضعف.

في هذه الدراسة تمت مقارنة مستوى إنزيم كرياتين كاينيز في امصال امهات الاطفال المصايين بمذا المرض ومقارنتها مع أمصال امهات لاطفال عاديين غير مصايين بمذا المرض فوجد زيادة ملحوظة في مستوى الامهات للاطفال المصايين وعند معاينة النتائج في مستوى هذا الانزيم عند الامهات للاطفال المصايين وجد ان هنالك زيادة كبيرة في هذا الانزيم بنسبة 52.1% وهذا يقودنا الى احتمالية ان 52.1% في هؤلاء والامهات هم حاملين للمرض و 47.9% هو نتيجة طفرة حديدة قد تكون بسبب عوامل بيئية عديدة.

# **Introduction**

uchenne muscular dystrophy(DMD) is the most common childhood form of muscular dystrophies(1).Early signs of DMD which usually occur between the ages of 2 and 6 years, include frequent falling, difficulty getting up from a sitting or position and awaddling lying gait(2). Another hallmark is the apparent enlargement of the calf muscle and sometimes other muscles which is really due to an accumulation of fat and connective tissue in the muscles. More over, a blood sample shows a very high level of serum

creatine kinase (SCK)(3), This enzyme catalyses the reversible transfer of a phosphate group from creatine phosphate to adenosine diphosphate forming creatine and adenosine triphosphate. The most likely explanation for high SCK levels in DMD is that the enzyme originates in muscles and escape into the serum. Breathing becomes affected during the later stages of DMD. Sever respiratory and heart problems mark the disease's final stages (4).

In 1986 the researches identified a rodshaped protein(dystrophin) which was absent or mutated in DMD patients(1). Antibodies used to study the dystrophin localization in muscles, it appear to be located in the sarcolema of normal muscles and was absent or markedly deficient in the patients with DMD (5,6).

The traditional clinical criteria for identifying amanifesting Duchenne carrier are positive family history, proximal limb weakness, calf hyperatrophy, high serum CK(7). Cardiomyopathy is often found in patient with DMD, and female carriers of DMD can develop symptomatic skeletal myopathy alone or combined with dilated cardiomyopathy(8).

### **Materials and method**

Blood samples were collected from (19)women(mothers of DMD patients) and from other (19)women with negative history of DMD as the control group for serum creatine kinase values.

#### Methods

Principle of the test:CK utilizes creatine phosphate and ADP as substrate to act as initial catalyst for a series of reaction resulting in the formation of NADPH as outlined in the coupled enzyme assay. The NADPH produced is proportional to CK activity and it is used to reduce into blue/violet color of diformazan which its absorption at 560nm. A reaction stopped by the addition of HCL as show in the following equations.

#### **Results**

Comparisons between serum CK levels of DMD patient s mothers and control group by using Student's paired t-test. A p-value<0.05 was considered statistically significant(10). The results indicate the serum creatine kinase levels of patient's mothers are significantly higher than serum CK levels of control group(p<0.05)(figure 1), and there are high increase in the levels of the serum CK in52.1% of patient's mothers which were ranging from 180 to 700 IU/L,while the normal values are 30-150 IU/L for female(11),table(1).

Table(1):Serum creatine kinase levels in DMD patient's mothers and control group.

### **Discussion**

There were high increase in serum CK levels of DMD patient's mothers in comparison with control group and there

was high increase in the levels of serum CK in52.1% of mother sof DMD patients while 47.9% ofmothers of DMD patients were within the normal range.CK is normally found in healthy muscles but if the muscles are diseased or damaged like DMD so large amounts of CK leak into the blood(11).Serum CK levels in carriers affected by genetic factors(13,14), so serum CK level can be used for detecting carriers of DMD(7).

The normal levels of serum CK in 49.9% of patient's mothers probably indicate that there were new mutations in the gene which is responsible for dystrophin production in the short arm of the x-chromosome, and this high rate of mutations because of the gene coding for dystrophin is one of the largest human genes recognized to date(2300KB) which helps explain the observation that approximately half of the cases of DMD are new mutations due to several mutagens which are found in our environment(14).

#### References

- Murray,R.K.;Granner,D.K.;Mayes,P. A. and Rodwell,V.W.(1996)Harper's biochemistry.Appleton and Lang, California.
- 2. Emery, A.E.H. (1993). Duchenne muscular dystrophy. Oxford Medical publication.
- Alvarez, L.M. and Morales, A.A. (1994). Relations between delayed diagnosis and forms of onset in Duchenne muscular dystrophy. Gac-Med-Mex. 130(6):459-64.
- 4. Patterson, V.; Morrison, O.; and Hicks, E. (1991). Mode of death in Duchenne muscular dystrophy. Lancet 337, 801-802.
- 5. Friedman, T. (1993). Progress toward human gene therapy. Science, 244.

6.Weis,K.;Shapira,Y.;Glick,B.;Lermansa gie,T.;Shahar,E.;Goez,H.;Kuta, M;Nevo,Y.(2007).Congenital myopathies in DMD families.J.Child.Neurol. 22(6)732-736.

7.Merlini,L.(1994).Calf myopathy with a twist.Neuromuscu-Disord.4(1):13-5.

Medical Journal of Babylon - 2008 Volume 5 No .1- المجلد الخامس - العدد الاول المجلة بابل الطبية 2008 المجلد الخامس - العدد الاول

8. Oldfors,A.;Eriksson,B.O.;Kyllerman, M.;Martinsson,T.andWahlstrom,J.(1 994).Dilated cardiomyopathy and the dystrophin gene:an illustrated review.Br.Heart.J.72(4):344-8.

9.Tietz,N.M.(1995).Clinical guide to lab.Tests,Philadelphia.pp3451.

10.Daniel, W.W.1983.Biostatistics. Afoun dation for analysis in the healthy sciences. Daniel, W.W.(ed) Johan Wiley and sons, New York.


11.Lundy, C.T.; Doherty, G.; Hicks, E. (20 07). Should creatine kinase be checked in all boys presenting with M.D. Arch Dis. Child. 92(7):697-699.

12.

Yazdanpanah, P.; Javan, A.; Nadaimi, B.; Shirazi, H.R. (2007). Genetic pattern of 3 cases of Emery-Dreifus muscular dystrophy in a family. East Mediterr Health J., 1:201-205.

13. Goodenhuis, M.A.; de Boone, "J.; Van der Kooi, A. (2007). Living with MD: health related quality of life consequences for children and adults. Health Qual Life Outoomes, 5:31-32.

14.Muchir, A.; Worman, H.J. (2007). Emer y muscular dystrophy. Curr Neurol Neurosc Rep. 1:78-83.




The procedure summarized in the following table:

standard Reagent blank Sample blank sample Color reagent 0.5ml 0.5ml0.5m10.5mlsolution Incubate for 3minutes at 37c° 0.05ml 0.05ml sample 0.05mlIncubate for 10 minutes at 37c° 0.1N HCL 5ml 5ml 5ml 5ml 0.05 mlsample Measures the absorbance at 560nm

CK activity(U/L)=(absorbance sample/absorbance standard)×standard concentration (9).

Serum CK levels of DMD patient s mothers(IU/L) 255 210 190 180 100 80 510 50 220 700 210 280 60 110 90 140	Serum CK levels of control group(IU/L) 110 60 130 90 140 70 50 60 80 60 150 80 40 120 90 50
120	140
=	-



Figure(1) Comparison between serum CK levels of control group and DMD patients mothers.